Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
|Videos|March 6, 2014
Daratumumab as a Potential Treatment Option for Multiple Myeloma
Author(s)Jacob Laubach, MD, MPP
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute and an Instructor in Medicine at the Harvard Medical School, discusses daratumumab as a potential treatment option for patients with multiple myeloma.
Advertisement
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute and an Instructor in Medicine at the Harvard Medical School, discusses daratumumab as a potential treatment option for patients with multiple myeloma.
Clinical Pearls:
- Daratumumab is a first-in-class CD38 monoclonal antibody
- Since CD38 is present on a number of other cell types, the first in-human dose-finding study proceeded cautiously with 0.005 mg/kg of the agent with dose escalation to 24 mg/kg
- At doses of 4 mg/kg or higher, the overall response rate, including minimal response, was over 60% and the rate of partial response or better was in the range of 40% to 45%, as defined as a 50% reduction in monoclonal protein
- Daratumumab was well tolerated but some infusion reactions were observed, specifically early on in the trial
- Daratumumab is now being studied in combination with other drugs, such as lenalidomide
Advertisement
Related to this article
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
2
Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma
3
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
4
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
5